AdAlta Raises $1.2M at 67% Premium to Advance Licensed PD1 CAR-T Therapy

AdAlta Limited (ASX: 1AD) has secured $1.2 million through a strategic placement to sophisticated investors at $0.005 per share, representing a 67% premium to its October 2025 placement price. The capital raise, which includes 240 million new shares and 120 million attaching options (exercisable at $0.01 by 3 June 2028), will strengthen the company’s ability to advance its recently licensed PD1 armoured MSLN CAR-T therapy, BZDS1901, and execute additional transactions under its “East to West” cellular immunotherapy strategy.

The placement follows the company’s 2 January 2026 announcement of licensing BZDS1901 from Shanghai Cell Therapy Group for advanced mesothelioma treatment. Managing Director Tim Oldham noted the premium pricing reflects market confidence in the strategic direction: “This investment, at a significant premium to the pre-BZDS1901 transaction price, puts us in a very strong position as we advance BZDS1901. We are grateful to the team and investors at 62 Capital who have followed on their previous investment, demonstrating the same confidence we feel in the future of our ‘East to West’ strategy.”

The placement, facilitated by lead manager 62 Capital Pty Ltd, attracted strong demand from new and existing professional investors. Settlement is expected on 26 January 2026, with trading of subscription shares and attaching options commencing 28 January 2026 under ASX codes 1AD (shares) and 1ADO (options).

What is AdAlta’s East to West cellular immunotherapy strategy?

AdAlta (ASX: 1AD) is implementing an “East to West” model designed to bridge Asian CAR-T innovation with Western regulatory markets. The strategy involves licensing advanced clinical-stage cellular immunotherapy products from Asian developers, particularly Chinese biotechnology companies, then conducting Phase I clinical studies in Australia before positioning them for out-licensing to larger biopharmaceutical partners for US and European commercialisation.

This approach capitalises on Asia’s rapid advancement in T cell therapy development whilst leveraging Australia’s efficient clinical trial infrastructure and US FDA-aligned regulatory framework. The model addresses a critical market gap: solid tumours, which account for 90% of cancers, remain significantly underserved by current cellular immunotherapies compared to blood cancers where CAR-T therapies have achieved regulatory approval.

CAR-T (Chimeric Antigen Receptor T-cell) therapy works by extracting a patient’s immune cells, genetically engineering them to recognise cancer-specific markers, then reinfusing them to target and destroy tumour cells. Whilst highly effective in certain blood cancers, solid tumours present additional challenges including immune suppression within the tumour microenvironment, a barrier AdAlta’s licensed BZDS1901 therapy specifically addresses through its PD1 armoured design.

The cellular immunotherapy market is projected to reach US$20.3 billion by 2028, growing at a compound annual growth rate of 34%. AdAlta positions itself within this high-growth segment by selecting highly differentiated clinical-stage assets with demonstrated efficacy data, reducing development risk compared to preclinical programmes.

Traditional vs. AdAlta’s “East to West” Development Model:

• Traditional Biotech Model: Internal R&D → preclinical studies → Phase I/II/III clinical trials → regulatory approval → commercialisation
• AdAlta’s “East to West” Model: Licence proven Asian clinical assets → Australian Phase I trials (FDA-aligned) → out-licensing to Western pharma partners for registrational studies

How will AdAlta use the placement funds for BZDS1901 development?

The $1.2 million raised through the placement will support three strategic priorities, all focused on advancing the company’s recently licensed BZDS1901 programme and expanding its cellular immunotherapy pipeline.

Fund allocation priorities:

1. AdCella equity participation: Proceeds will enable AdAlta to increase its ownership stake in AdCella, the “East to West” operating subsidiary established to house the BZDS1901 asset and future licensed products. The company has previously announced significant progress towards securing third-party financing for AdCella, and this capital provides negotiating leverage to maintain or enhance AdAlta’s equity position during those discussions.

2. FDA regulatory engagement: Funds will accelerate regulatory advice costs related to establishing the US FDA pathway for BZDS1901. This includes pre-IND (Investigational New Drug) meeting preparation and related activities critical to positioning the therapy for US clinical development following Australian Phase I studies.

3. Pipeline expansion: The capital will support evaluation and negotiation of additional licensing opportunities to expand AdCella’s product portfolio beyond BZDS1901, consistent with the company’s strategy of building a diversified pipeline of differentiated CAR-T therapies for solid cancers.

The placement strengthens AdAlta’s negotiating position as it progresses third-party financing discussions for AdCella. Management has indicated that securing external capital for the subsidiary would allow AdAlta to participate in that financing round whilst maintaining strategic control, creating a capital-efficient structure that aligns with the company’s replicable business model.

CEO Tim Oldham emphasised the timing significance: “Following the licensing of BZDS1901 from Shanghai Cell Therapy Group, we are moving rapidly towards commencing our development activities, securing financing in our operating subsidiary AdCella and adding further opportunities to our pipeline.”

Placement structure and terms

The placement issued 240 million ordinary shares at $0.005 per share alongside 120 million attaching options on a one-for-two basis (one option for every two shares subscribed). The attaching options carry an exercise price of $0.01 with an expiry date of 3 June 2028 (ASX: 1ADO), providing investors with leveraged exposure to potential share price appreciation.

The 67% premium to AdAlta’s October 2025 placement price of $0.003 signals renewed investor confidence following the BZDS1901 licensing announcement, though the issue price represents a 17% discount to the 12 January 2026 closing price of $0.006.

62 Capital Pty Ltd, which led the placement, will receive a 6% fee on gross proceeds (excluding GST), settled in shares and options on identical terms to the placement. Additionally, 62 Capital will receive 75 million lead manager options exercisable at $0.01 with the same 3 June 2028 expiry, issued at $0.000001 per option. The lead manager’s repeat participation following previous AdAlta placements demonstrates ongoing conviction in the company’s strategic direction.

Securities will be issued utilising AdAlta’s existing placement capacity under ASX Listing Rules 7.1A (in respect of 229,526,904 ordinary shares) and 7.1 (in respect of 202,200,000 options and 24,873,096 ordinary shares), avoiding the need for shareholder approval and enabling rapid capital deployment.

CEO Commentary on Premium Pricing

“This investment, at a significant premium to the pre-BZDS1901 transaction price, puts us in a very strong position as we advance BZDS1901. We are grateful to the team and investors at 62 Capital who have followed on their previous investment, demonstrating the same confidence we feel in the future of our ‘East to West’ strategy,” said Tim Oldham, CEO and Managing Director.

What makes AdAlta’s PD1 armoured MSLN CAR-T therapy differentiated?

BZDS1901, licensed from Shanghai Cell Therapy Group on 2 January 2026, combines two complementary mechanisms to address a critical limitation of existing CAR-T therapies in solid tumours: the immunosuppressive tumour microenvironment that allows cancer cells to evade immune attack.

The therapy targets mesothelin (MSLN), a protein overexpressed in mesothelioma and several other solid cancers including ovarian, pancreatic, and lung cancers. Mesothelin-targeted therapies have shown promise in clinical studies, but their effectiveness has been limited by the tumour’s ability to suppress immune responses through checkpoint proteins like PD1 (Programmed Death-1).

BZDS1901’s “PD1 armoured” design addresses this challenge by incorporating a mechanism that blocks the PD1 checkpoint pathway directly within the CAR-T cell structure. When tumour cells attempt to suppress the engineered T cells via PD1 signalling, the armoured CAR-T cells resist this suppression, maintaining their cancer-killing activity within the hostile tumour microenvironment.

This dual-action approach (mesothelin targeting combined with built-in PD1 resistance) represents a significant advancement over first-generation CAR-T therapies that lack mechanisms to overcome immune suppression. For mesothelioma patients, who face limited treatment options and poor prognosis following diagnosis, BZDS1901 offers potential for meaningful clinical benefit in a disease setting with high unmet medical need.

The therapy’s clinical-stage status further differentiates it from preclinical programmes. Shanghai Cell Therapy Group has generated efficacy and safety data that de-risks the asset compared to earlier-stage CAR-T constructs, positioning AdAlta to advance Australian Phase I studies with greater confidence in the therapeutic concept.

BZDS1901’s three key competitive advantages:

1. Dual-mechanism design: Combines MSLN-targeting for cancer cell recognition with PD1 checkpoint blockade to overcome tumour immune suppression, addressing a major failure mode of CAR-T therapies in solid tumours.

2. Clinical-stage validation: Licensed with existing efficacy and safety data from Shanghai Cell Therapy Group, reducing development risk compared to preclinical CAR-T constructs requiring initial proof-of-concept studies.

3. Australian regulatory pathway: Phase I trials in Australia’s FDA-aligned regulatory framework enable efficient clinical validation whilst positioning the asset for US market access through established out-licensing partnerships with larger biopharmaceutical companies.

Timeline and next steps

Settlement of the placement is scheduled for 26 January 2026, with allotment and commencement of trading for both subscription shares (ASX: 1AD) and attaching options (ASX: 1ADO) expected on 28 January 2026.

Near-term investor focus will centre on AdCella financing announcements and FDA regulatory pathway confirmation. The company has previously disclosed significant progress towards securing third-party financing for AdCella, with negotiations ongoing. Completion of this subsidiary-level capital raise would provide clarity on AdAlta’s ultimate equity stake and the operational structure supporting BZDS1901 development.

FDA pre-IND meeting outcomes, anticipated during H1 2026, will establish the regulatory pathway requirements for progressing BZDS1901 towards US clinical studies following Australian Phase I completion. These discussions will define chemistry, manufacturing, and controls expectations, clinical trial design parameters, and the evidentiary requirements for advancing to pivotal studies.

Upcoming milestones for investor consideration:

• 28 January 2026: Commencement of trading for subscription shares (1AD) and attaching options (1ADO)
• H1 2026: AdCella third-party financing announcement, clarifying subsidiary ownership structure and capital deployment timeline
• H1 2026: FDA regulatory pathway confirmation following pre-IND meeting discussions
• Ongoing: Additional “East to West” licensing opportunities to expand AdCella’s clinical-stage CAR-T pipeline beyond BZDS1901

AdAlta has established an InvestorHub platform where shareholders can access updates and engage in discussions regarding company developments. The platform provides a centralised resource for tracking BZDS1901 progress, AdCella financing milestones, and pipeline expansion activities as the “East to West” strategy advances.

The $1.2 million capital raise at a 67% premium to previous placement pricing positions AdAlta (ASX: 1AD) to execute on its cellular immunotherapy strategy whilst the company navigates critical financing and regulatory milestones during 2026. The 120 million attaching options exercisable at $0.01 by June 2028 provide investors with leveraged exposure to potential value creation as BZDS1901 progresses through Australian clinical development towards US market positioning.

Interested In AdAlta’s Groundbreaking Cellular Immunotherapy Pipeline?

AdAlta’s recent $1.2 million capital raise fuels development of its PD1 armoured MSLN CAR-T therapy, BZDS1901, advancing solid tumour treatments in a high-growth $20 billion market. This funding strengthens their “East to West” strategy, bridging Asian innovation with US and European regulatory pathways.

To explore how AdAlta is revolutionising cancer treatment and discover investment opportunities, visit the AdAlta investor centre for full project details and latest updates.